Results 11 to 20 of about 354,280 (226)

Er(r)go...

open access: yesEr(r)go, 2016
Wojciech Kalaga Institute of English Cultures and Literatures Faculty of Philology University of Silesia in Katowice Poland Er(r)go... failure of speech – please be silent, because silence is the treasure hold of sounds, their saturation, the ...
Wojciech Kalaga
doaj   +2 more sources

Health‐Related Quality of Life and Symptom Severity Among Patients With PIK3CA‐Related Overgrowth Spectrum: A Mixed‐Methods Study to Understand Real‐World Experience With Alpelisib Treatment

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background PIK3CA‐related overgrowth spectrum (PROS) includes several rare overgrowth disorders resulting from somatic gain‐of‐function mutations in PIK3CA. Despite treatment advances, including the recent approval of alpelisib for PROS in the United States, literature detailing the patient experience with PROS is limited.
Vamsi Bollu   +8 more
wiley   +1 more source

Venous Thromboembolism in Pediatric Bone Sarcoma Patients: A 10‐Year, Single‐Institution Experience Encompassing the COVID‐19 Pandemic

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Osteosarcoma (OS) and Ewing sarcoma (EWS) are the most common primary bone cancers in children, but acute thrombosis is poorly characterized in this population. Our study evaluated the rates of venous thromboembolism (VTE) and associated risk factors in pediatric patients with bone sarcomas treated over a 10‐year period encompassing
Sarah Kappa   +8 more
wiley   +1 more source

Er(r)go...

open access: yesEr(r)go, 2015
Wstęp autorstwa redaktora naczelnego wprowadzający kluczowe zagadnienia dla współczesnej teorii literatury i kultury, a także komentujący zagadnienia, którym poświęcony jest niniejszy numer.
Wojciech Kalaga
doaj   +2 more sources

Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with acute lymphoblastic leukemia (ALL) are at risk of severe outcomes from SARS‐CoV‐2 (SCV2). In the post‐pandemic context, where most children have been infected with SCV2, there are limited data on whether vaccination remains beneficial in children with ALL.
Janna R. Shapiro   +11 more
wiley   +1 more source

Er(r)go...

open access: yesEr(r)go, 2014
Er(r)go… , … civilization—progress and order—as a source of fear. Paradoxically, civilization protects us from fear, eliminating threats that originate in nature, but at the same time it amplifies fear, giving birth to its own breed of threats.
Wojciech Kalaga
doaj   +2 more sources

Er(r)go... [PDF]

open access: yes, 2012
"Er(r)go…, ... czas zajrzeć do wnętrz(a), choć to pojęcie dziś niemal wstydliwe, przywołujące widma binaryzmów. Zaglądajmy jednak, nie zważając na teoretyczne fobie.
Kalaga, Wojciech
core  

Deep Sequencing of FLT3‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 (FLT3‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3‐ITD during and after treatment has shown prognostic ...
Sofie Johansson Alm   +11 more
wiley   +1 more source

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook   +6 more
wiley   +1 more source

ER(R)GO nr 2 (1/2001)

open access: yes, 2001
Pełnotekstowa wersja "Er(r)go" nr 2 (1 ...
Er(r)go, Redakcja
core   +1 more source

Home - About - Disclaimer - Privacy